About Penta
Who we are
Diversity and Inclusion
Penta ID Network
Penta Foundation Italy
Penta Foundation UK
Penta ID Innovation
Annual reports
Our Activities
News & Events
News
Press center
Penta Newsletter
Stories
Scientific Views
Penta Aperitivo Webinars
Publications
Contact us
Work with us
Vacancies
Call for services
Diversity & Inclusion
Brighter Future Award
PENTA 20 (Odyssey)
Publications
HIV
Dolutegravir-based ART is superior to NNRTI- and PI-based ART in infants, children and adolescents living with HIV (combined results of the main trial and the ‘under 14kg’ cohort)
29 Jul, 2021
Authors:
Turkova A on behalf of the ODYSSEY trial team
Presented at
:
CHIVA 2021